Analysis ofKRASMutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing
Open Access
- 21 December 2010
- journal article
- research article
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2010, 1-5
- https://doi.org/10.1155/2010/789363
Abstract
Due to the call for fast KRAS mutation status analysis for treatment of patients with monoclonal antibodies for metastatic colorectal cancer, sensitive, economic, and easily feasible methods are required. Under this aspect, the sensitivity and specificity of the SNaPshot analysis in comparison to the commonly used DNA sequencing was checked. We examined KRAS mutations in exon 2 codons 12 and 13 with DNA sequencing and SNaPshot analysis in 100 formalin-fixed paraffin-embedded tumor tissue samples of pancreatic carcinoma, colorectal carcinoma, and nonsmall cell lung cancer specimens of the primary tumor or metastases. 40% of these samples demonstrated mutated KRAS genes using sequencing and SNaPshot-analysis; additional five samples (45/100) were identified only with the SNaPshot. KRAS mutation detection is feasible with the reliable SNaPshot analysis method. The more frequent mutation detection by the SNaPshot analysis shows that this method has a high probability of accuracy in the detection of KRAS mutations compared to sequencing.Keywords
This publication has 16 references indexed in Scilit:
- Review article: panitumumab ‐ a fully human anti‐EGFR monoclonal antibody for treatment of metastatic colorectal cancerAlimentary Pharmacology & Therapeutics, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnnals of Oncology, 2007
- FDA Drug Approval Summary: Panitumumab (Vectibix™)The Oncologist, 2007
- Hyperactive Ras in developmental disorders and cancerNature Reviews Cancer, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal CancerCancer Research, 2006
- Sensitive Sequencing Method for KRAS Mutation Detection by PyrosequencingThe Journal of Molecular Diagnostics, 2005
- ras oncogenes in human cancer: a review.1989